DS
RLMD icon

David Shaw’s Relmada Therapeutics RLMD Stock Holding History

David Shaw’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Buy
+109,474
New +$765K ﹤0.01% 3940
2024
Q1 		– Sell
-10,649
Closed -$44.1K – 4669
2023
Q4 		$44.1K Sell
10,649
-8,829
-45% -$26.1K ﹤0.01% 4029
2023
Q3 		$58.4K Sell
19,478
-23,239
-54% -$69K ﹤0.01% 3905
2023
Q2 		$105K Sell
42,717
-1,245
-3% -$3.44K ﹤0.01% 3824
2023
Q1 		$99.4K Buy
43,962
+28,290
+181% +$97.5K ﹤0.01% 3982
2022
Q4 		$54.7K Sell
15,672
-62,534
-80% -$549K ﹤0.01% 4430
2022
Q3 		$2.9M Buy
+78,206
New +$2.17M ﹤0.01% 2669
2022
Q2 		– Sell
-10,487
Closed -$283K – 5705
2022
Q1 		$283K Buy
+10,487
New +$217K ﹤0.01% 4682

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's RLMD Position: Q2 2026 in Review

David Shaw opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 109,474 shares worth $758K. The stake represents ﹤0.01% of the portfolio and ranks #3940 among its holdings. This is a return to the name: David Shaw previously reported a position in RLMD as recently as Q4 2023.

David Shaw first reported a position in RLMD in Q1 2022 and has held it in 8 quarters since. The position peaked at $2.9M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • David Shaw held 109,474 shares of Relmada Therapeutics worth $758K as of Q2 2026.
  • Relmada Therapeutics was a new David Shaw position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3940 holding.
  • David Shaw first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • David Shaw's Relmada Therapeutics position peaked at $2.9M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.